Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned: the descriptive characterization of apixaban as an oral anticoagulant is supported by the provided label excerpt, but multiple indication/usage claims cannot be verified from the provided label sections, and no critical safety labeling elements (e.g., contraindications, boxed warning, dosing specifics) are assessed.
Category Scores
Accurate Statements
Apixaban is an oral anticoagulant (a blood thinner).
11 DESCRIPTION: apixaban is described as a factor Xa (FXa) inhibitor and ELIQUIS is an oral dosage form, supporting anticoagulant/blood-thinner characterization.
Unsupported Statements
Apixaban is used to reduce the risk of blood clots.
The provided excerpts do not include the actual Indications and Usage wording; definitive support cannot be confirmed from the supplied label text.
Apixaban is used for blood clot risk in atrial fibrillation.
Atrial fibrillation indication text is not present in the supplied label sections.
Apixaban is used for treatment of venous thromboembolism.
Venous thromboembolism treatment indication text is not present in the supplied label sections.
Apixaban is used for prevention of venous thromboembolism.
Venous thromboembolism prevention indication text is not present in the supplied label sections.
Contradictions
Important Omissions
Boxed Warning
Importance:
Moderate
Contraindications
Importance:
Moderate
Dosage and Administration details (including dosing safety/dose adjustments and administration instructions)
Importance:
Moderate
Warnings and Precautions
Importance:
Moderate
Use in specific populations (e.g., pregnancy/lactation, pediatrics) and related labeling
Importance:
Moderate
Drug interactions
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Indication/usage claims (atrial fibrillation and venous thromboembolism treatment/prevention) cannot be verified from the provided label excerpts; additionally, critical safety labeling elements were not evaluated from the label sections supplied.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Indication/usage claims are not verifiable from the supplied label excerpts, and critical safety sections were not assessed.
Suggested Improvement
Cite the exact Indications and Usage text for each claimed use (blood clot risk reduction, atrial fibrillation, venous thromboembolism treatment, and prevention) and evaluate key safety sections from the label (Boxed Warning, Contraindications, Warnings/Precautions, Dosage and Administration, and Drug Interactions).